Healthcare Cost Containment

Amgen Announces Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric Patients With Heterozygous Familial Hypercholesterolemia At ESC Congress 2020 | PR Newswire | 8/29/2020

… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability …

New Amgen Data To Be Presented At ESC Congress 2020 Highlighting RepathaÂŽ (evolocumab) Efficacy In High-Risk Patient Populations | PR Newswire | 8/25/2020

… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability …

Follow Healthcare Cost Containment:    

FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens | PR Newswire | 8/21/2020

… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability …

Amgen Announces Pricing Terms For Senior Notes Exchange Offers, Increases The Maximum Notes Exchange Cap And Accepts Tendered Notes | PR Newswire | 8/14/2020

… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …

Amgen Announces Early Tender Results Of Senior Notes Exchange Offers | PR Newswire | 8/13/2020

… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …

Study: Shift from Highest-Priced Healthcare Providers Would Generate Tremendous Savings | PRWeb | 8/10/2020

… at the Pioneer Institute. She was also a former Senior Fellow and Associate at the Harvard Kennedy School’s Center for Business and Government where she researched and wrote about Massa­chusetts market reform and healthcare cost containment efforts. She served as Massachusetts Undersecretary of the Office of Consumer Affairs and Business Regulation from 2009 to 2015 and has worked at the intersection of federal and state commercial regulation and the …

Varicella Zoster Infection Treatment Market to Witness Widespread Expansion During 2017 - 2027 | 8/5/2020

… cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment , primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at …

Containing Rising Healthcare Costs in the Wake of COVID-19 | Modern Healthcare | 7/31/2020

… but there has never been a better time to engage in creative thinking about ways to contain healthcare costs and simultaneously serve the needs of vulnerable citizens. HMS has extensive experience helping states with healthcare cost containment strategies. Visit Health Ideas , our forum to discuss the latest healthcare issues and trends including our newest blog series on cost containment. Sponsored By: HMS advances healthcare by helping organizations reduce costs and …

Amgen Commences Exchange Offers For Certain Series Of Outstanding Senior Notes From Exchange Eligible Holders | PR Newswire | 7/30/2020

… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …

Indivior Announces Agreement to Resolve Criminal Charges and Civil Complaints Related to SUBOXONE® Film | PR Newswire | 7/24/2020

… be achieved; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment ; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group’s products and product candidates; risks related to …

Amgen Announces 2020 Third Quarter Dividend | PR Newswire | 7/23/2020

… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …

Appeals Court Affirms Validity Of Enbrel® (etanercept) Patents Injunction Against Sandoz’s Infringement Stands | PR Newswire | 7/1/2020

… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …

New Data from the RECOVER™ Study Reveal Two-Year Outcomes in People with Opioid Use Disorder Following Transition from Pivotal Phase 3 Clinical Trials to a Real-World Setting | PR Newswire | 6/24/2020

… be achieved; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment ; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group’s products and product candidates; risks related to …

ClaimsBridge Welcomes Michael Tosti as Executive Vice President of Sales and Marketing | The Wapakoneta Daily News | 6/24/2020

Company seeks to accelerate their growth in healthcare cost containment solutions ARNOLD, MD, June 24, Innovative Healthware Services, DBA ClaimsBridge, ( www.claimsbridge.com ), a leading healthcare technology company providing solutions that help control medical claim costs, announced that Michael Tosti has been hired to the position of Executive Vice President of Sales and Marketing. In this role, Tosti will be responsible for driving the growth of IHS’s ClaimsBridge suite of IT solutions …

Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries | PR Newswire | 6/22/2020

… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …

Rheumatoid Arthritis Treatment Market: Business Analysis, Scope, Size, Share, Growth, Trends | 6/8/2020

… cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment , primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at …

City of Phoenix Council Shows Leadership in Helping Phoenix Children’s Respond to COVID-19 Financial Impact | PR Newswire | 5/7/2020

PHOENIX , May 7, On Wednesday, the City of Phoenix City Council authorized the City Manager to enter into an inter-governmental agreement with the Arizona Healthcare Cost Containment System (AHCCCS) to utilize the City’s Pediatric Health Care Initiative Ordinance. The authorization continues a long partnership between Phoenix Children’s Hospital and the City of Phoenix. The Pediatric Health Care Initiative Ordinance, which was extended in 2019, enables the City to accept …

Amgen Reports First Quarter 2020 Financial Results | PR Newswire | 5/1/2020

… policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment . Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with …

PFIZER REPORTS FIRST-QUARTER 2020 RESULTS | Business Wire | 4/28/2020

… vaccine or product candidate and any pricing and access challenges for such products; trade buying patterns; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment , and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; the impact of any significant spending reductions or cost controls affecting Medicare, Medicaid or other …

Global Connected Drug Delivery Devices Market to Generate Lucrative Revenue Prospects for Manufacturers After the End of COVID-19 Crisis | 4/24/2020

… cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment , primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at …

Global Gait Trainer Market to Undergo Rapid Advancements During the COVID-19 Period | 4/24/2020

… cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment , primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at …

Global Ultrasound Conductivity Gels Market to Record Robust Growth Rate in the Next 10 Years After the End of COVID-19 Crisis | 4/24/2020

… cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment , primary care delivery, innovation in medical procedures (3-D printing, block chain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted …

Global Female Pelvic Implants Market to Undergo Rapid Advancements During the COVID-19 Period | 4/24/2020

… cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment , primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at …

Increasing Demand for Vulvodynia Treatment to Substantially Surge the Revenues Through the COVID-19 Lockdown Phase | 4/24/2020

… cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment , primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at …

Fast-Paced Growth in End-use Adoption after COVID-19 pandemic to Propel Varicella Zoster Infection Treatment Market Revenue Growth | 4/24/2020

… cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment , primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at …

COVID-19

Containing Rising Healthcare Costs in the Wake of COVID-19 | Modern Healthcare | 7/31/2020

COVID-19 has been devastating for the American healthcare system. Hospitals are struggling with high demand for emergency and inpatient care, while non-emergency surgical services and outpatient care have plummeted. Meanwhile, the pandemic has … of vulnerable citizens. HMS has extensive experience helping states with healthcare cost containment strategies. Visit Health Ideas , our forum to discuss the latest healthcare issues and trends including our newest blog series on cost containment …

Department of Health and Human Services

Indivior Announces Agreement to Resolve Criminal Charges and Civil Complaints Related to SUBOXONE® Film | PR Newswire | 7/24/2020

… stipulated injunction with the FTC, and entered into a Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services (HHS). Under the terms of the agreement, the Justice … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …

Medicaid

City of Phoenix Council Shows Leadership in Helping Phoenix Children’s Respond to COVID-19 Financial Impact | PR Newswire | 5/7/2020

… the City of Phoenix City Council authorized the City Manager to enter into an inter-governmental agreement with the Arizona Healthcare Cost Containment System (AHCCCS) to utilize the City’s Pediatric Health Care Initiative Ordinance. The … Children’s has worked with state and local government to mitigate Medicaid payment losses. “Phoenix Children’s is grateful to Mayor Gallego, members of the City Council and to the City’s legal and finance staff for collaborating …

Consumer Healthcare

PFIZER REPORTS FIRST-QUARTER 2020 RESULTS | Business Wire | 4/28/2020

… Meridian and Mylan-Japan are reported in Pfizer’s Upjohn business in all periods presented. Acquisitions and the contribution of Pfizer’s Consumer Healthcare business to the GSK Consumer Healthcare joint venture (JV) that were completed during … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; the impact of any …

American Heart Association

Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol | PR Newswire | 3/28/2020

… for greater research into the efficacy and safety of PCSK9 inhibitors in specific populations, like people living with HIV. The American Heart Association and American College of Cardiology multi-society cholesterol guidelines also identify HIV … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …

Psychosocial Support

New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes | PR Newswire | 12/2/2019

… a minimum of seven days. SUBLOCADE should be used as part of a complete treatment program that includes counseling and psychosocial support. 2 “This analysis offers new insight into extended-release buprenorphine treatment in patients … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …

Mental Health

New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes | PR Newswire | 12/2/2019

… Department of Family Medicine, David Geffen School of Medicine, UCLA . “These results showed that patients experienced improvements in physical and mental health which may help in the recovery journey and positively impact lifestyle, including employment … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …

Addiction Treatment

New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes | PR Newswire | 12/2/2019

… program that includes counseling and psychosocial support. IMPORTANT SAFETY INFORMATION Prescription use of this product is limited under the Drug Addiction Treatment Act. WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …

Mental Health Services

New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes | PR Newswire | 12/2/2019

… in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims … Department of Health and Human (HHS), Services Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment (SAMHSA). Medication-Assisted Treatment for Opioid Addiction . HHS Publication No. (SMA) 09-4443, First printed 2009. Revised …

Clinical Data

Amgen Announces Data Being Presented At ASH 2019 | PR Newswire | 12/2/2019

THOUSAND OAKS, Calif. Amgen (NASDAQ: AMGN ) today announced new clinical data from its oncology in-line products and pipeline that will be presented at the 61 st American Society of Hematology (ASH) Annual Meeting & Exposition … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …

Biosimilars

Amgen Announces Data Being Presented At ASH 2019 | PR Newswire | 12/2/2019

… biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing …

National Cancer Institute

Amgen Announces Data Being Presented At ASH 2019 | PR Newswire | 12/2/2019

… B-ALL) were accepted as a late-breaking abstract. AALL1331 is sponsored by the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI), part of the National Institutes of Health, and is conducted by … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …

Food and Drug Administration

Amgen Announces Data Being Presented At ASH 2019 | PR Newswire | 12/2/2019

… potential to treat a wide variety of cancers. BLINCYTO was granted breakthrough therapy and priority review designations by the U.S. Food and Drug Administration and is approved in the U.S. for the treatment of: relapsed … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …

National Institutes of Health

New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes | PR Newswire | 12/2/2019

… in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims … Health and Human Services (HHS), National Institute on Drug Abuse, National Institutes of Health. Drugs, Brains, and Behavior: The Science of Addiction. HHS Publication No. (SMA) 18-5063PT5, Printed 2018. 6. Ling W, Nadipelli VR, Solem …

Substance Abuse

New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes | Yahoo News | 12/2/2019

… injections on patient-centered outcomes: a long-term study “ was published online in the December issue of the Journal of Substance Abuse Treatment ( https://doi.org/10.1016/j.jsat.2019.11.004 ). 1 By the end of the 12 … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …

Medicare

New Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function | PR Newswire | 11/18/2019

… providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to … HK, Kielhorn A et al. Economic burden of hospitalizations of Medicare beneficiaries with heart failure. Risk Manag Healthc Policy . 2017; 10: 63-70. 10. Jhund PS, MacIntyre K, Simpson CR, et al. Long-Term Trends in …

Clinical Research

Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors | PR Newswire | 11/15/2019

THOUSAND OAKS, Calif. , Nov. 15, 2019 /PRNewswire/ – Amgen (NASDAQ: AMGN ) in collaboration with the Duke Clinical Research Institute (DCRI) today announced plans to initiate the C ardio v ascular M ulti-dimensional Ob servational I … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …

Electronic Health Records

Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors | PR Newswire | 11/15/2019

… imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims …

Behavioral Health

Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder (OUD) and to Let People with OUD Know That They Can “Keep Moving Towards Recovery” | PR Newswire | 11/11/2019

… in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims … No. PEP19-5068, NSDUH Series H-54. Rockville, MD : Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/ . Accessed on November 7, 2019 . SOURCE Indivior Related …

Committee for Medicinal Products for Human Use

EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture | PR Newswire | 10/18/2019

… BRUSSELS , Oct. 17, Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) today announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …

Precision Medicine

Four New Tech Applications Improving Payment Accuracy, Interoperability | FierceHealthcare | 10/7/2019

… so many groundbreaking applications of AI in healthcare , and the possibilities are, quite literally, limitless. From medical image analysis to precision medicine to administrative efficiency, AI is having a profound impact on the way we … but in fact, robotics is playing an important role in healthcare cost containment. Using software-based robotics process automation, we are able to streamline many of the complex functions required to identify and address improper …

EDIS

Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show – Company Announcement - FT.com | Financial Times | 6/12/2019

… damage and disability, having a substantial impact on quality of life,” said Dr. Philip J. Mease, Director of Rheumatology Research, Swedish Medical Center/Providence St Joseph Health and Clinical Professor, University of Washington School of … actions or delays or government regulation generally; global trends toward healthcare cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain …

American Society of Clinical Oncology

Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019 | PR Newswire | 6/3/2019

… mutant solid tumors. These data are being presented during an oral session at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago . “KRAS has been a target of active … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …

ACA

Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting | PR Newswire | 5/2/2019

… that it will present new long-term data of Aimovig ® (erenumab-aooe) across the migraine spectrum at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia . Data from a one-year open-label … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …

Pharmaceutical Supply Chain

PFIZER REPORTS FIRST-QUARTER 2019 RESULTS | Business Wire | 4/30/2019

… buying patterns; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or … impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our revenues and on patient confidence in the integrity of our medicines; the end result of any negotiations between the U.K …

Amgen

Amgen Announces Pricing Terms For Senior Notes Exchange Offers, Increases The Maximum Notes Exchange Cap And Accepts Tendered Notes | PR Newswire | 8/14/2020

THOUSAND OAKS, Calif. , Aug. 13, Amgen Inc. (NASDAQ: AMGN ) announced today the pricing terms of its previously announced nine separate private offers to exchange (each, an “Exchange Offer” and, collectively, the “Exchange Offers”) certain specified … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …

Amgen Announces Early Tender Results Of Senior Notes Exchange Offers | PR Newswire | 8/13/2020

THOUSAND OAKS, Calif. , Aug. 13, Amgen Inc. (NASDAQ: AMGN ) announced today the early tender results of its previously announced nine separate private offers to exchange (each, an “Exchange Offer” and, collectively, the “Exchange Offers”) certain … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …

BeiGene

Amgen Announces 2020 Third Quarter Dividend | PR Newswire | 7/23/2020

… ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19), BeiGene, Ltd., or the Otezla® (apremilast) acquisition, including anticipated Otezla sales growth and the timing … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …

Amgen Announces 2020 Second Quarter Dividend | PR Newswire | 3/4/2020

… deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations with any other company, including BeiGene, Ltd., or the Otezla ® (apremilast) acquisition, including anticipated Otezla sales growth and the timing … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …

Sandoz

Appeals Court Affirms Validity Of Enbrel® (etanercept) Patents Injunction Against Sandoz’s Infringement Stands | PR Newswire | 7/1/2020

… United States District Court for the District of New Jersey that had upheld the validity of two patents asserted against Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (together, Sandoz) based on Sandoz’s biosimilar of … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …

Appeals Court Affirms Validity Of Enbrel® (etanercept) Patents Injunction Against Sandoz’s Infringement Stands | Yahoo News | 7/1/2020

… United States District Court for the District of New Jersey that had upheld the validity of two patents asserted against Sandoz Inc., Sandoz International GmbH and Sandoz GmbH (together, Sandoz) based on Sandoz’s biosimilar of … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …

Pfizer

PFIZER REPORTS FIRST-QUARTER 2020 RESULTS | 4/28/2020

NEW YORK–(BUSINESS WIRE)–Apr 28, 2020– Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2020, reaffirmed its 2020 financial guidance for revenues and Adjusted diluted EPS (3) and updated certain other components … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; the impact of any …

PFIZER REPORTS FIRST-QUARTER 2019 RESULTS | Business Wire | 4/30/2019

NEW YORK- Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2019 and raised the midpoint of its 2019 financial guidance for adjusted diluted EPS (2) . At the start of the 2019 fiscal year … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; the impact of any …

GSK

PFIZER REPORTS FIRST-QUARTER 2020 RESULTS | Business Wire | 4/28/2020

… reported in Pfizer’s Upjohn business in all periods presented. Acquisitions and the contribution of Pfizer’s Consumer Healthcare business to the GSK Consumer Healthcare joint venture (JV) that were completed during 2019 impacted financial results in … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; the impact of any …

Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased – Company Announcement - FT.com | Financial Times | 7/18/2019

… prior year which benefited from a USD 5.7 billion net gain recognized from the sale of our stake in the GSK consumer healthcare joint venture. EPS was USD 0.91. Core operating income was USD 3.6 … could be affected by, among other things: global trends toward healthcare cost containment, including ongoing government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; regulatory actions or delays or …

Upjohn

PFIZER REPORTS FIRST-QUARTER 2020 RESULTS | Business Wire | 4/28/2020

… 2020 and 2019 (4) are summarized below. OVERALL RESULTS ($ in millions, except per share amounts) First-Quarter Beginning in 2020, Upjohn began managing Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; the impact of any …

PFIZER REPORTS FIRST-QUARTER 2019 RESULTS | Business Wire | 4/30/2019

… portfolio into its Oncology and Inflammation & Immunology business units and certain legacy established products into the Internal Medicine business unit. Upjohn, a global, off-patent branded and generic established medicines business, which includes 20 off … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products; the impact of any …

Adaptive Biotechnologies

Amgen And Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strategic Collaboration | PR Newswire | 4/8/2020

THOUSAND OAKS, Calif. , and SEATTLE , April 7, Amgen (NASDAQ: AMGN ) and Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) will participate in a webinar hosted by Bernstein on Thursday, April 9 at 8 a.m. PT ( 11 a.m. ET … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …

Amgen And Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strategic Collaboration | Markets Insider | Business Insider | 4/7/2020

THOUSAND OAKS, Calif. , and SEATTLE , April 7, 2020 /PRNewswire/ – Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies Corporation (NASDAQ:ADPT) will participate in a webinar hosted by Bernstein on Thursday, April 9 at 8 a.m. PT ( 11 … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …

Novartis

Amgen, Novartis And Banner Alzheimer’s Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer’s Prevention | PR Newswire | 7/12/2019

THOUSAND OAKS, Calif. , July 11, Amgen (NASDAQ: AMGN ), Novartis and Banner Alzheimer’s Institute today announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …

Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting | PR Newswire | 5/2/2019

… including time spent with family and friends, or at work. 2,3 Aimovig, co-commercialized in the U.S. by Amgen and Novartis, is the first and only FDA-approved treatment that prevents migraine by targeting the … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …

Allergan

FDA Approves Amgen And Allergan’s KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab) | PR Newswire | 6/14/2019

THOUSAND OAKS, Calif. , June 13, Amgen (NASDAQ: AMGN ) and Allergan plc (NYSE: AGN ) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI ™ (trastuzumab-anns) for all approved indications of the reference … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …

Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer | PR Newswire | 11/10/2017

Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer First Avastin® (Bevacizumab) Biosimilar Candidate Recommended for European Approval 10, 2017, 07:27 THOUSAND OAKS, Calif … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …

JMP Securities

BV Investment Partners Announces Investment in Franco Signor | Markets Insider | Business Insider | 4/25/2019

… care deeply about.” Vikrant Raina , Managing Partner of BV Investment Partners, said, “We recognize the importance of MSP compliance within healthcare cost containment efforts and, furthermore, recognize Franco Signor as a true leader in this … Franco Signor is BV’s eighth investment in its ninth fund. JMP Securities LLC served as exclusive financial advisor to Franco Signor in connection with the transaction. Seyfarth Shaw LLP represented Franco Signor as counsel in …

BV Investment Partners Announces Investment in Franco Signor | PR Newswire | 4/25/2019

… care deeply about.” Vikrant Raina , Managing Partner of BV Investment Partners, said, “We recognize the importance of MSP compliance within healthcare cost containment efforts and, furthermore, recognize Franco Signor as a true leader in this … Franco Signor is BV’s eighth investment in its ninth fund. JMP Securities LLC served as exclusive financial advisor to Franco Signor in connection with the transaction. Seyfarth Shaw LLP represented Franco Signor as counsel in …

Brigham and Women's Hospital

Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack | PR Newswire | 11/16/2019

… patients 1 ,” said Robert Giugliano , M.D., FOURIER executive committee member and a senior investigator at the TIMI Study Group at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School . “These results demonstrate … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …

New Analyses Presented At AHA 2017 Show Repatha® (evolocumab) Significantly Reduced Cardiovascular Events In Patients With Peripheral Artery Disease And In Patients With A History Of Heart Attacks | PR Newswire | 11/13/2017

… achieved with statins alone,” said Marc Sabatine , M.D., chairman, TIMI Study Group, Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine, Brigham and Women’s Hospital and lead investigator of FOURIER. “These results offer additional ways for … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …

Mayo Clinic

Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019 | Markets Insider | Business Insider | 6/16/2019

… providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to … cancer/acute-lymphoblastic-leukaemia-all/about. Accessed June 10 , 2019. Mayo Clinic. Acute lymphocytic leukemia. https://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/basics/definition/con-20042915. Accessed June 10, 2019 . View original content to download …

Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019 | PR Newswire | 6/16/2019

… providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to … cancer/acute-lymphoblastic-leukaemia-all/about . Accessed June 10 , 2019. Mayo Clinic. Acute lymphocytic leukemia. http://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/basics/definition/con-20042915 . Accessed June 10, 2019 . SOURCE Amgen Related Links http …

Walter Ling

New Data from the RECOVER™ Study Reveal Two-Year Outcomes in People with Opioid Use Disorder Following Transition from Pivotal Phase 3 Clinical Trials to a Real-World Setting | PR Newswire | 6/24/2020

… 2020 . “Opioid use disorder is a chronic disease and its treatment is complex and multifaceted,” said the study’s lead author, Walter Ling , MD, Research Professor, Department of Family Medicine, David Geffen School of Medicine, UCLA … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …

David M. Reese

Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries | PR Newswire | 6/22/2020

… potential for patients suffering from ENL and TB, two diseases that continue to challenge many countries around the world,” said David M. Reese , M.D. executive vice president of Research and Development at Amgen. “We believe … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …

Robert A. Bradway

Amgen Reports First Quarter 2020 Financial Results | PR Newswire | 5/1/2020

… Amgen and others across the industry are stepping up to meet the greatest public health challenge of our lifetime,” said Robert A. Bradway , chairman and chief executive officer. “We are committed to an uninterrupted supply … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …

Christian Heidbreder

SUBLOCADE® Long-Term Safety Data Published in Journal of Clinical Psychopharmacology | PR Newswire | 4/16/2020

… opioid use disorder as a chronic disease that requires services and support structures over an extended period of time,” said Christian Heidbreder , PhD, Indivior’s Chief Scientific Officer. “Data from this open-label study provide additional … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; challenges in the commercial execution; claims and concerns that may arise …

David Reese

Amgen And Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strategic Collaboration | PR Newswire | 4/8/2020

… imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our …

Jessica Akopyan

New Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function | PR Newswire | 11/18/2019

… providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to … Corporate Communications, Investor Relations (415) 290-7757 CONTACT: Amgen, Thousand Oaks Jessica Akopyan, (805) 447-0974 (media) Trish Hawkins , 805-447-5631 (media) Arvind Sood , 805-447-1060 (investors) CONTACT: Servier Sonia Marques : [email protected] – Tel. +33 (0)1 55 72 …

Arvind Sood

New Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function | PR Newswire | 11/18/2019

… providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to … Oaks Jessica Akopyan, (805) 447-0974 (media) Trish Hawkins , 805-447-5631 (media) Arvind Sood , 805-447-1060 (investors) CONTACT: Servier Sonia Marques : [email protected] – Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13 …

Darryl Sleep

Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack – Company Announcement - FT.com | Financial Times | 11/16/2019

… are not managing one of the most important modifiable risk factors for a heart attack: high LDL-C 2 ,” said Darryl Sleep , M.D., senior vice president of Global Medical and chief medical officer at Amgen … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …

Shaun Thaxter

Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder (OUD) and to Let People with OUD Know That They Can “Keep Moving Towards Recovery” | PR Newswire | 11/11/2019

… that medication, including counseling, is available to help them treat their addiction and help them keep moving towards recovery,” said Shaun Thaxter , Chief Executive Officer of Indivior. “We believe that those suffering from moderate to … regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy …

David Nicholson

FDA Approves Amgen And Allergan’s KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab) | PR Newswire | 6/14/2019

… Herceptin. “KANJINTI is the second of four biosimilars from Amgen and Allergan’s collaboration to be approved by the FDA,” said David Nicholson , chief research and development officer at Allergan. “We are proud of the progress … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …

David Nichol

FDA Approves Amgen And Allergan’s KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab) | PR Newswire | 6/14/2019

… Herceptin. “KANJINTI is the second of four biosimilars from Amgen and Allergan’s collaboration to be approved by the FDA,” said David Nicholson , chief research and development officer at Allergan. “We are proud of the progress … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …

Franco Signor

BV Investment Partners Announces Investment in Franco Signor | Markets Insider | Business Insider | 4/25/2019

… firm focused on the business services, software and IT services sectors, today announced that it has made an investment in Franco Signor , a provider of Medicare Secondary Payer (MSP) compliance solutions to the country’s largest … Partners, said, “We recognize the importance of MSP compliance within healthcare cost containment efforts and, furthermore, recognize Franco Signor as a true leader in this space, helping its customers navigate ever-evolving and complex rules …

Sean E. Harper

FDA Approves Amgen’s Repatha® (evolocumab) To Prevent Heart Attack And Stroke | CNBC | 12/2/2017

… priority so that patients can benefit from Repatha’s ability to reduce life-changing events of heart attacks and strokes,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “Despite treatment … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our …

Sean Harper

FDA Approves Amgen’s Repatha® (evolocumab) To Prevent Heart Attack And Stroke | PR Newswire | 12/1/2017

… imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims …

Cindy McDaniel

Amgen Launches The ENBREL Mini™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For Patients | PR Newswire | 11/17/2017

… are happy to award the ENBREL Mini™ cartridge with AutoTouch™ reusable autoinjector with our Ease of Use SM Commendation,” said Cindy McDaniel , senior vice president, Consumer Affairs, The Arthritis Foundation. “This distinction is awarded to … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen’s …

Joan Lunden

Award-Winning Journalist And Cancer Survivor Joan Lunden Partners With Amgen To Launch ’At Home | PR Newswire | 10/24/2017

… NASDAQ: AMGN ) today announced the launch of At Home with Joan , a campaign led by breast cancer survivor and advocate Joan Lunden . This campaign aims to empower patients diagnosed with cancer to be active participants … developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We …